Designing A Pivotal Phase 3 CML Trial Around Physician Choice And Patient Quality Of Life
A conversation between Enliven Therapeutics Chief Medical Officer Helen Collins, MD, and Clinical Leader Executive Editor Abby Proch

Patients with chronic myeloid leukemia (CML) can now expect a normal or nearly normal life expectancy, but that often means decades of daily therapy, side effects, dosing restrictions, and resistance that could lead many to switch treatments.
Enliven Therapeutics hopes its investigational highly selective ATP-competitive inhibitor, relcobatinib (ELVN-001), can offer a better option. In its Phase 3 ENABLE-2 trial, Enliven will randomize patients previously treated with at least one tyrosine kinase inhibitor (TKI) to relcobatinib 80 mg once daily or the investigator’s choice of dasatinib, nilotinib, or bosutinib. The trial will compare major molecular response (MMR) rates, safety, tolerability, and patient-reported outcomes.
In this Q&A, Enliven Chief Medical Officer Helen Collins, MD, explains how Phase 1 findings helped shape the trial design, why the company chose a multidrug comparator arm, what a randomized study can show that a single-arm trial can’t, and how a positive result could change CML treatment decisions.
Clinical Leader: Where do current CML treatments still fall short?
Helen Collins, MD: Many patients with CML have a normal or nearly normal life expectancy. This has changed what we want from treatment. When patients are going to be living with their disease for decades, potentially taking medication every day for the rest of their lives, it's no longer enough just to control the leukemia. We also want treatments that are well tolerated, easy to take, and allow patients to maintain a good quality of life.
However, many of the current treatments have off-target effects that create tolerability issues, as well as potential drug-drug interactions. Some also require patients to either take their medication with food or fast before and after dosing. Together, these challenges can affect how patients feel and structure their day.
There is also still work to be done on the efficacy front. The goal is to help more patients achieve a deep molecular response and eventually treatment-free remission. Today, only about one in five patients achieves and maintains this goal. Resistance also remains a challenge, and as newer therapies become more widely used, we are identifying additional resistance mutations, including mutations associated with allosteric inhibitors, which create additional questions and unknowns for doctors and patients.
These challenges are reflected in how often patients switch therapies. Approximately 25% of patients receiving first-line treatment and 30% receiving second-line treatment switch therapy within the first year. Generally, patients switch treatment for one of three reasons: the CML becoming resistant or never responding, the patient not tolerating the treatment or having persistent low-grade side effects, and changes in their overall health or other medications that require a treatment switch.
Ultimately, we’re not just treating the leukemia. We’re managing a chronic disease over decades, and our goal is to find the treatment that provides the best disease control while allowing patients to live as normally as possible.
Which findings from the ELVN-001 Phase 1 trial most influenced your Phase 3 design?
In June, we announced updated positive Phase 1 clinical data and alignment with the FDA on key Phase 3 trial design components. The Phase 1b cohort data supported selection of an 80 mg once-daily dose for Phase 3. In the Phase 1b cohort data, 61% of 28 patients were in MMR by Week 24. Importantly, 48% of the patients who were not in MMR at baseline achieved MMR by the same time point.
What’s particularly encouraging is the population in which we’re seeing these responses. Most patients in our Phase 1 study had previously received at least three TKIs, and more than half had been previously treated with asciminib. These are patients who have already received multiple treatments, so achieving meaningful MMR in this population is particularly important.
We’ve also observed a favorable safety and tolerability profile across the 158 patients treated at the different doses studied in Phase 1, which was another important consideration in selecting the dose for Phase 3. Taken together, these findings supported our decision to advance relcobatinib (ELVN-001) into Enliven’s ENABLE-2 pivotal Phase 3 trial, where we will evaluate its efficacy and safety compared with second-generation TKIs in patients who have received at least one prior treatment for CML.
Were there operational or clinical lessons that impacted how Phase 3 will be run?
As we announced our updated Phase 1 results in June, we also aligned with the FDA on the 80 mg once-daily dose and the inclusion of patients previously treated with one or more TKIs in the ENABLE-2 pivotal Phase 3 trial.
We've designed the trial to answer questions that matter to patients and treating physicians: If someone with CML needs to change treatment and would ordinarily receive a second-generation TKI, would relcobatinib offer a better chance of achieving an MMR? And would they tolerate that treatment better?
The trial will compare MMR rates at different time points, alongside safety and tolerability, against investigator-selected second-generation TKIs. We've also included patient-reported outcome measures to understand how patients feel and how treatment affects their quality of life.
We're also considering relcobatinib's longer-term potential for newly diagnosed patients, with early planning underway for a first-line trial potentially beginning in 2028.
Why the comparator strategy, and how will the trial account for differences among agents?
Through this trial, we hope to establish relcobatinib as a best-in-class ATP-competitive inhibitor that can play an important role as patients move between CML therapies. In CML, there isn't one treatment that's right for every patient. Physicians select therapies based on a patient's prior treatment history, response to previous drugs, other medical conditions, and the safety and tolerability profiles of the available treatments.
That's why we chose to compare relcobatinib with the investigator's choice of three established second-generation TKIs: dasatinib, nilotinib, or bosutinib. This approach reflects how treatment decisions are made in clinical practice and allows us to evaluate relcobatinib against relevant treatment options rather than a single drug.
The trial is designed to compare relcobatinib with these three agents as a combined comparator group. Although the individual drugs have different efficacy and safety profiles, the randomized design allows us to assess the overall efficacy and tolerability of relcobatinib compared with these established treatment options.
What does a randomized trial against active comparators show that a single-arm study couldn’t?
A single-arm study can tell us how patients respond to relcobatinib, but it can't reliably tell us whether they would have done better or worse on another available treatment. That's why a randomized trial is so important.
In ENABLE-2, patients will be randomized to receive either relcobatinib or one of three established second-generation TKIs selected by their physician. By studying these treatments in comparable patient populations, over the same period, and using the same assessments, we can directly evaluate how relcobatinib compares in terms of efficacy, safety, and tolerability.
Importantly, the trial also includes patients previously treated with asciminib, reflecting how the CML treatment landscape is evolving.
Ultimately, we want to understand whether the encouraging efficacy and tolerability we've seen in Phase 1 translate into meaningful advantages over existing treatments. ENABLE-2 is designed to provide the evidence needed to support a potential regulatory approval and to help physicians make informed treatment decisions for their patients.
What challenges do you anticipate in running a Phase 3 CML trial?
One challenge is enrolling patients into a randomized trial when there are already effective treatments available. Patients and their physicians need to feel comfortable with either treatment they might receive. That's why we've designed ENABLE-2 to compare relcobatinib with established second-generation TKIs, allowing physicians to select the comparator most appropriate for each patient.
If ENABLE-2 is successful, how could it change treatment decision-making?
ENABLE-2 has the potential to provide physicians with an important new treatment option for patients with previously treated CML. By directly comparing relcobatinib with second-generation TKIs, the trial will help physicians understand how it compares in terms of efficacy, safety, and tolerability, and where it might fit best into treatment decisions.
That matters because treating CML involves more than achieving a molecular response. Patients may be taking medication for decades, so maintaining disease control while minimizing the burden of daily therapy is critical.
Ultimately, the opportunity is to raise expectations for what CML treatment can offer. We want patients not only to live longer but also to live better.
About The Expert:
Helen Collins, MD, chief medical officer at Enliven Therapeutics, is a board-certified oncologist and former medical oncologist and hematologist.